Sellas Sinks 18% as Phase 3 Leukemia Trial Reaches “Critical Milestone” Ahead of Final Data
Sellas Life Sciences' stock fell 18% after announcing its Phase 3 REGAL trial in acute myeloid leukemia reached the 80th death, triggering final analysis. The trial took longer than expected, and topline results are due this quarter. Sellas had $138 million in cash at June 30. According to the CEO, a successful trial could lead to an FDA filing.
How this was made
The 30-second read
Why it matters
The milestone prompted an 18% intraday decline, reflecting investor uncertainty ahead of overall‑survival results due later this quarter.
Market read
The trial milestone is a material catalyst for SLS, driving a sharp price move and creating short‑term trading opportunities.
What to watch
Cash runway of $138 million provides runway for continued operations, reducing immediate bankruptcy risk.
Background
Sellas Life Sciences reported that its pivotal Phase 3 REGAL trial in AML reached the 80th death, a pre‑specified trigger for final analysis.
Ticker impact
Shares fell 18% after Sellas announced its Phase 3 REGAL trial reached the 80th death, triggering final analysis.
likely pressure as the market prices in uncertainty over the upcoming topline data
The trial milestone caused an immediate 18% drop; without survival data, traders may continue to sell.
Market effects
Biotech sector may see heightened volatility as other companies with pending trial data are re‑priced.
U.S. biotech stocks could see modest pullback in pre‑market trading.
Limited to investors focused on clinical‑trial outcomes; no broad market effect.
Counterpoint
If the upcoming survival data exceeds expectations, the stock could rebound sharply from the oversold level.
Key entities
- CompanySellas Life Sciences
Biotech firm developing galinpepimut‑S (GPS) as maintenance therapy for AML.
- ExecutiveAngelos Stergiou
CEO of Sellas who described the milestone as critical.
